Dr. Lal PathLabs Limited has informed stock exchanges about an upcoming board meeting scheduled for January 30, 2026, where directors will review the company's third quarter performance and consider dividend distribution to shareholders.

Board Meeting Agenda

The board meeting will address two primary matters for the diagnostic services company. Directors will consider and approve the unaudited financial results for both standalone and consolidated operations covering the quarter and nine months ended December 31, 2025.

Dividend Consideration

The board will also deliberate on the declaration of a third interim dividend on equity shares for the financial year 2025-26. The company has indicated that the dividend declaration remains subject to board approval and may not be finalized depending on various factors considered during the meeting.

Regulatory Compliance

Dr. Lal PathLabs submitted this intimation to both the National Stock Exchange of India Limited and BSE Limited on January 23, 2026. The communication serves as a continuation of an earlier intimation dated December 29, 2025, which initially announced the board meeting for Q3FY26 results consideration.

The announcement was signed by Vinay Gujral, Company Secretary and Compliance Officer, ensuring proper regulatory disclosure requirements are met ahead of the scheduled board meeting.

Dr. Lal PathLabs Limited has announced that its Board of Directors will meet on January 30, 2026, to consider and approve the company's unaudited financial results for the third quarter of fiscal year 2026. The meeting will address both standalone and consolidated financial results for the quarter and nine months ending December 31, 2025. Additionally, the company will host an earnings conference call on the same day to discuss the financial and operating performance with investors and analysts.

Board Meeting Details

The healthcare company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will specifically focus on reviewing and approving the unaudited financial performance for the specified period.

Earnings Conference Call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Dr. Lal PathLabs will host an earnings conference call for investors and analysts on Friday, January 30, 2026, at 4:00 PM IST. The call will discuss the financial and operating performance for Q3 & 9M FY26.

The conference call will begin with a brief discussion by management on Q3 & 9M FY26 financial and operating performance, followed by a question-and-answer session for participants.

Trading Window Closure

In compliance with regulatory requirements, Dr. Lal PathLabs has announced the closure of its trading window for company securities. This measure aligns with the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code for Prevention of Insider Trading.

Company Overview

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brands in diagnostic services with an integrated nationwide network. The company offers a broad range of diagnostic and related healthcare tests and services, with a catalogue including 385 test panels, 3,172 pathology tests and 1,455 radiology and cardiology tests. The company operates 298 clinical labs, 6,607 Patient Service Centers and 12,365 Pick-up Points, processing approximately 86 million samples from 28.8 million patients.